Systemic sclerosis and the gastrointestinal tract. Diagnostic and therapeutic approach;Esclerosis sistémica y tracto gastrointestinal. Abordaje diagnóstico y terapéutico

Reumatologia Clinica

Volumn 2, Issue SPEC. ISS. 3, 2006, Pages 24-30

  Vera Lastra, Olga Lidia ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Clinical manifestation; Diagnosis; Gastrointestinal tract; Systemic sclerosis; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CIPROFLOXACIN; CISAPRIDE; COLCHICINE; CONTRAST MEDIUM; DOMPERIDONE; ERYTHROMYCIN; METOCLOPRAMIDE; METRONIDAZOLE; MISOPROSTOL; NORFLOXACIN; OCTREOTIDE; PROBIOTIC AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; TEGASEROD; TETRACYCLINE;

ABDOMINAL DISTENSION; ANUS DISEASE; ARTICLE; BACTERIAL OVERGROWTH; CLINICAL FEATURE; COLON DISEASE; COLON DIVERTICULOSIS; CONSTIPATION; DIARRHEA; DYSPHAGIA; ENDOSCOPY; ESOPHAGUS DISEASE; FECES INCONTINENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE MOTILITY; INTESTINE OBSTRUCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALABSORPTION; MANOMETRY; NAUSEA; PH MEASUREMENT; RECTUM DISEASE; SMALL INTESTINE DISEASE; STOMACH DISEASE; STOMACH EMPTYING; STOMACH PARESIS; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS;

EID: 33846245479     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Vera Lastra O. Esclerosis sistémica. Med Int Mex. 2006;22:231-45.
2. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998; 27:563-94.
3. Young MA, Rose S, Reynolds JC. Gastrointestinal manifestations of scleroderma. Rheum Dis Clin North Am. 1996;22:797-823.
4. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;15:691-712.
5. Bassotti G, Battaglia E, Debernardi V, Germani U, Quiriconi F, Dughera L, et al. Esophageal dysfunction in scleroderma. Arthritis Rheum. 1997; 40:2252-9.
6. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestation of systemic sclerosis. Sem Arthritis Rheum. 1994;24:29-39.
7. Hamel-Roy J, Devroede G, Arhan P, Tetreault L, Duranceau A, Menard H. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology. 1985;88:1-7.
8. Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspect. Baillieres Clin Rheumatol. 2000;14:1-16.
9. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-controlled study of the pathology of oesophageal disease in systemic [epub antes de imprenta] Gut. 2006; Mar 9.
10. a ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 293-317.
11. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-44.
12. Dantas RO, Aprile LR. Esophageal striated muscle contractions in patients with gastroesophageal reflux symptoms Dig Dis Sci. 2002;47:2586-90.
13. Jaovisidla K, Csuka ME, Almargo UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Seminars Arthritis Rheum. 2004;34:689-702.
14. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over period of 14 years: using a modified Medsges scale. Ann Rheum Dis. 2001;60:1117-22.
15. Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum. 2005;59:2882-8.
16. Niv Y, Abu-Avid S, Yelin A, Liberman Y. Barrett's ephithelium and esophageal adenocarcinoma in scleroderma. Am J Gastroeneterol. 1988; 83:792-3.
17. Heath EI, Limburg PJ, Hawk ET, et al. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Huntingt). 2000;14:507-14.
18. Contreras MA, Salas C, Andreu JL, Mulero J. Cytomegalovirus esophagitis as a treatable complication of systemic sclerosis. J Clin Rheumatol. 2001;7:384-7.
19. Marie I, Dominique S, Levesque H, Durcrotte P, Denis P, Hellot MF, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45:346-54.
20. Ing AJ. Interstitial lung disease and gastroesophageal reflux. Am J Med. 2001;111 Suppl 8A:S41-4.
21. Al-Amri SM. The pattern of esophageal manometry in progressive systemic sclerosis. Sandi Med J. 2003;24:68-71.
22. Bestetti A, Carola F, Condato L, Marasini B, Torolo GL. Esophageal scintigraphy with a semisolid meal to evaluate esophageal dysmotility is systemic sclerosis and Raynaud's phenomenon. J Nucl Med. 1999;40:77-84.
23. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazol: a controlled study in normal subjects. Gastroenterology. 1998;115:1335-9.
24. Gillen D, Wirz AA, Ardill JE. Rebound hypersecretion alter omeprazol and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116:239-47.
25. Mercado U, Arroyo de Anda R, Avendano L, Araiza-Casillas R, Avendano-Reyes M. Metodopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. Clin Exp Rheumatol. 2005;23:685-8.
26. Vera Lastra O, Rodríguez Molinar LE, Normandia Almeida A, Rodríguez Alejandre A, Lira Carreon CE, Jara LJ, et al. Utilidad de la eritromicina en la gastroparesia por esclerodermia. Estudio comparativo con metoclopramida. Rev Mex Reumat. 2001;16:361-6.
27. Linke R, Meier M, Muenzing W, Folwaczny C, Schnell O, Tatsch K. Prokinetic therapy: what can be measured by gastric scintigraphy? Nucl Med Commun. 2005;26:527-33.
28. Marie I, Levesque H, Ducrotté P, Denis P, Hellot MF, Benichou J, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroeneterol. 2001;96:77-83.
29. Sridhar KR, Lange RC, Magyar L, Soykan I, McCallun RW. Prevalence of impaired gastric of solid in systemic sclerosis: diagnosis and therapeutic implications. J Lab Clin Med. 1998;132:541-6.
30. Allescher HD, Bockanhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scan J Gastroenterol. 2001;36:934-41.
31. Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJC. Effect of cisapride on gastric and esophageal empting in progressive systemic sclerosis. Gastroeneterology. 1987;93:311-5.
32. Wang SJ, La SJ, Chen DY, Chen YH, Hsieh TY, Lin WY. Effects cisapride on oesophageal transit of solid in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21:43-5.
33. Enger C, Call C, Walker AM. Serious ventricular arrhythmias among user of cisapride and other QT-prolonging agent in the United States. Pharmacoepidemiol Drug Saf. 2002:11:477-86.
34. Dull J, Rautman JP, Zakai D, Strashun A, Straus EW. Successful treatment of gastroparesis with erythromycin in a patient with progressive systemic sclerosis. Am J Med. 1990;89:528-9.
35. Annese V, Janssen J, Vanteappen G, Tack J, Peeters TL, Willeinse P, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenetrology. 1992; 102:823-8.
36. Fiorucci S, Distrutti E, Gerli R, Morelli A. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastrenterol. 1994;89: 550-5.
37. Miller LS, Szych GA, Kantor SB, Bromer MQ, Knight LC, Maurer AH, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol. 2002;97: 1653-60.
38. Watson M, Hally RJ, McCue PA, Vasga J, Jimenez SA. Gastric antral estasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheum. 1996;39:341-6.
39. Elkayam O, Oumanski M, Yaron M, Caspi D. Watermelon stomach following and preceding systemic sclerosis. Seminars Arthritis Rheum. 2000;30:127-31.
40. Binmoeller KF, Katon RM. Bipolar electrocoagulation for watermelon stomach. Gastrointest Enclosc. 1990;36:399-402.
41. Rose JDR. Endoscopic injection of alcohol for bleeding from gastroduodenal vascular anomalies. Br Med J. 1987;295:93-4.
42. Vera Lastra O, Mayoral J, Baltazar Montufar P, Ramírez Mendoza P, Ariza Andraca R. Alteraciones gastroesofágicas y factores de riesgo condicionantes en pacientes con esclerodermia. Med Int Mex. 1996; 12 Supl:53.
43. Attar A. Digestive manifestations in systemic sclerosis. Ann Med Interne (Paris). 2002;153:260-4.
44. Boerner RM, Fried DB, Warshauer DM, Isaacs K. Pneumatosis intestinalis: two cases reports and a retrospective review of the literature from 1985 to 1995. Dig Dis Sci. 1996;41:272-85.
45. Toskes PP. The changing nature of small intestine bacterial overgrowth. Curr Gastroenetrol Rep. 1999;1:267-8.
46. Hirano I, Pandolfino J. Chronic intestinal pseudo-obstruction. Dig Dis. 2000;18:83-92.
47. Mann SD, Debinsky HS, Kamm MA. Clinical characteristic of chronic idiopathic intestinal pseudo-obstruction in adults. Gut. 1997;41:675-81.
48. Toskes PP. The changing nature of small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 1999;1:267-8.
49. Shanahan F, McCarthy J. Functional foods and probiotic: time for gastroenterologist to embrace the concept. Curr Gastroenterol Rep. 2000;2:345-6.
50. Attar A, Fluorie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999; 117:794-7.
51. Boeckxstaens GE, Bertelsman JFWM, Lauwers L, Tytgat GNJ. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gatroenterol. 2002;97:197-7.
52. Soudan HC, Hasler WL, Owyang C. Effect of octeotride on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461-7.
53. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octeotride and erythromycin on idiopathic and scleroderma-associated intestinal pseudo-obstruction. Dig Dis Sci. 1995;40:1892-901.
54. Lecomte T, Cavicchi M, Delchier JC. Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin. Gastroenterol Clin Biol. 2000;24:361-3.
55. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet. 2002;41:1021-42.
56. Corsetti M, Tack J. Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome. Exp Opin Pharmacother. 2002;3: 1211-8.
57. Wald A. Slow transit constipation. Curr Treat Options Gastroenetrol. 2002;5:279-83.
58. Haque U, Yardley J, Talamini M, Wigley F. Colon stricture and volvulus in a patient with scleroderma. J Rheumatol. 1999;26:2268-72.
59. Hamel-Roy J, Devroede G, Arhan P, Tetreault L, Duranceau A, Menard HA. Comparative esophageal and anorrectal motility in scleroderma. Gastroenterology. 1985;88:1-8.
60. Leighton JA,Valdovinos MA, Pemberton JH, Rath DM, Camilleri M. Anorrectal dysfunction and rectal prolapse in progressive systemic sclerosis. Dis Colon Rectum. 1993;36:182-5.
61. Wang SJ, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Colonic transit disorders in systemic sclerosis. Clin Rheumatol. 2001;20:251-4.
62. Bharucha AE, Phillips SF. Slow transit constipation. Gastroenterol Clin North Am. 2001;30:77-97.
63. Wang SJ, Lan JL, Lan JL, Chen DY, Chen YH, Hsieh TY, et al. Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21:271-4.
64. Norton C, Kamm MA. Anal sphincter biofeedback and pelvic floor exerrise for faecal incontinence in adults: a systematic review. Aliment Pharmacol Ther. 2000:15:1147-95.
65. Heymen S, Jones KR, Ringel Y, Scarlett Y, Whitehead WE. Biofeedback treatment of fecal incontinente: a critical review. Dis Colon Rectum. 2001;44:728-36.
66. Burr AD. Primary cirrhosis and other ductopenic disease. Clin Liver Dis. 2002;6:363-80.
67. Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorder and primary biliar cirrhosis: an appraisal of 170 italian patients. Ann Rheum Dis. 2001;60:1046-9.
68. Yaussef WI, Tavil AS. Connective tissue disease and liver. J Clin Gastroenterol. 2002;35:345-9.
69. Walker NJ, Zurier RB. Liver abnormalities in rheumatic disease. Clin Liver Dis. 2002;6:933-46.
70. Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388-94.
71. Akimoto S, Ishikawa O, Muso Y, Takagi H, Tamura T, Miyachi Y. Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliar cirrhosis: a comparison with patients with systemic sclerosis alone. J Dermatol. 1999;26:18-22.
72. Stadie V, Wohlrab J, Marsch WC. Reynolds syndrome - a rare combination of 2 autoimmune diseases. Med Klin (Munich). 2002;97:40-3.
73. Mackay IR. Autoimmunity and primary biliar cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:519-33.
74. Kaplan MM. Medical progress: primary biliar cirrhosis. N Eng J Med. 1996;335:1570-80.
75. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-20.
76. Pases A, Rodes J. Treatment of primary biliary cirrhosis. Minerva Gastroenterol Dietol. 2000;46:165-74.